Search Results - "Gianni, A.M."

Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes by Giannatempo, P., Greco, T., Mariani, L., Nicolai, N., Tana, S., Farè, E., Raggi, D., Piva, L., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Avuzzi, B., Maffezzini, M., Landoni, G., De Braud, F., Gianni, A.M., Sonpavde, G., Salvioni, R., Necchi, A.

“…After a comprehensive review and meta-analysis, radiotherapy and chemotherapy appeared to be similarly effective overall in clinical stage (CS) IIA and IIB…”
Get full text

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group by Ryan, G., Martinelli, G., Kuper-Hommel, M., Tsang, R., Pruneri, G., Yuen, K., Roos, D., Lennard, A., Devizzi, L., Crabb, S., Hossfeld, D., Pratt, G., Dell'Olio, M., Choo, S. P., Bociek, R. G., Radford, J., Lade, S., Gianni, A. M., Zucca, E., Cavalli, F., Seymour, J. F.

“…Background: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and…”
Get full text

174 Quantification of 3D Tumor Vessel Networks by Vessel Caliber, Amount and Distribution, Allows Comparison Among Effects of Vascular-targeted Therapies by Righi, M, Giacomini, A, Cleris, L, Gianni, A.M, Carlo-Stella, C

Get full text

48 Proffered Paper: The BH3-only Protein Bim Plays a Critical Role in Hodgkin Lymphoma Cell Death Triggered by the HDAC Inhibitor Givinostat and the Multikinase Inhibitor Sorafenib by Locatelli, S.L, Guidetti, A, Cleris, L, Gianni, A.M, Anichini, A, Carlo-Stella, C

Get full text

PD-0526: Relationship between extension of radiation fields and second primary cancers in early stage Hodgkinís Lymphoma by Di Russo, A, Viviani, S, Cosentino, V, Pignoli, E, Magazzù, D, Valagussa, P, Gianni, A.M

Get full text

960 Combining Vascular Disruption Activity of TRAIL-expressing CD34+ Cells With Antiangiogenic Activity of Sorafenib Improves Regression of Tumor Growth by Giacomini, A, Lavazza, C, Grazia, G, Locatelli, S.L, Cleris, L, Righi, M, Gianni, A.M, Carlo-Stella, C

Get full text

436 Interleukin-8 (IL8) and Transforming Growth-Factor Beta (TGF-β) as Drugable Biomarkers of Response, Progression-free (PFS) and Overall Survival (OS) with Pazopanib (PZP): a Phase II Study in Relapsed Urothelial Cancer (UC) by Necchi, A, Zaffaroni, N, Mariani, L, Giannatempo, P, Nicolai, N, Pennati, M, Daidone, M.G, Gianni, A.M, De Braud, F.G, Salvioni, R

Get full text

7157 POSTER INT70/09 Phase II Study of Pazopanib (PZP) Monotherapy for Patients (pts) With Relapsed/refractory Urothelial Cancer (UC) – Updated Results by Necchi, A, Nicolai, N, Ortega, C, Sava, T, Sacco, C, Crippa, F, Morosi, C, Zaffaroni, N, Gianni, A.M, Salvioni, R

Get full text

Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies by CORRADINI, P, ZALLIO, F, PATRIARCA, F, RAMBALDI, A, SCIME, R, LOCASCIULLI, A, BANDINI, G, GIANNI, A. M, TARELLA, C, OLIVIERI, A, MARIOTTI, J, FARINA, L, BREGNI, M, VALAGUSSA, P, CICERI, F, BACIGALUPO, A, DODERO, A, LUCESOLE, M

“…Older age and a previously failed autologous stem-cell transplantation (SCT) are poor prognostic factors for patients receiving myeloablative conditioning and…”
Get full text

248 Targeting TRAIL receptors with genetically-engineered CD34+ stem cells by Carlo-Stella, C, Gianni, A.M

Get full text

537 Potent in vitro and in vivo anti-tumor activity of ITF2357 by modulation of c-myc related miRNA signature in human Burkitt's lymphoma by Zappasodi, R, Iorio, M.V, Cavanè, A, Magni, M, Ruggiero, G, Carlo-Stella, C, Croce, C.M, Gianni, A.M, Nicola, M. Di

Get full text

602 Identification of HSP105 as a novel non-Hodgkin lymphoma restricted antigen by Pupa, S.M, Zappasodi, R, Ghedini, G.C, Castagnoli, L, Aiello, P, Miccichè, F, Cabras, A.D, Bongarzone, I, Gianni, A.M

Get full text

7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial by Nicola, M. Di, Necchi, A, Nicolai, N, Bengala, C, Siena, S, Novarino, A, Carlo-Stella, C, Piva, L, Gianni, A.M, Salvioni, R

Get full text

P158 Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer by Milani, R, Zanni, M, Dodero, A, Spina, F, Testi, A, Tarella, C, Bernardi, M, Gallamini, A, Bandini, G, Benedetti, F, Gianni, A.M, Corradini, P

Get full text

P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients by Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, K, Ciceri, F, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, A.M, Tarella, C

Get full text

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue by Ciavarella, S., Vegliante, M.C., Fabbri, M., De Summa, S., Melle, F., Motta, G., De Iuliis, V., Opinto, G., Enjuanes, A., Rega, S., Gulino, A., Agostinelli, C., Scattone, A., Tommasi, S., Mangia, A., Mele, F., Simone, G., Zito, A.F., Ingravallo, G., Vitolo, U., Chiappella, A., Tarella, C., Gianni, A.M., Rambaldi, A., Zinzani, P.L., Casadei, B., Derenzini, E., Loseto, G., Pileri, A., Tabanelli, V., Fiori, S., Rivas-Delgado, A., López-Guillermo, A., Venesio, T., Sapino, A., Campo, E., Tripodo, C., Guarini, A., Pileri, S.A.

“…Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the…”
Get full text

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue by Ciavarella, S., Vegliante, M.C., Fabbri, M., De Summa, S., Melle, F., Motta, G., De Iuliis, V., Opinto, G., Enjuanes, A., Rega, S., Gulino, A., Agostinelli, C., Scattone, A., Tommasi, S., Mangia, A., Mele, F., Simone, G., Zito, A.F., Ingravallo, G., Vitolo, U., Chiappella, A., Tarella, C., Gianni, A.M., Rambaldi, A., Zinzani, P.L., Casadei, B., Derenzini, E., Loseto, G., Pileri, A., Tabanelli, V., Fiori, S., Rivas-Delgado, A., López-Guillermo, A., Venesio, T., Sapino, A., Campo, E., Tripodo, C., Guarini, A., Pileri, S.A.

Get full text

Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma by Guidetti, A., Mazzocchi, A., Miceli, R., Paterno’, E., Taverna, F., Spina, F., Crippa, F., Farina, L., Corradini, P., Gianni, A.M., Viviani, S.

“…•TARC levels significantly decrease after one cycle of ABVD in HL patients.•Cut-Off of 800pg/ml after one cycle allows to identify patients with good…”
Get full text

784 Quantification and molecular profiling of circulating tumour cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages by Necchi, A, Fina, E, Giannatempo, P, Colecchia, M, Iacona, C, Farè, E, Nicolai, N, Salvioni, R, Gianni, A.M, Mariani, L, Daidone, M.G, Cappelletti, V

Get full text

1123 Activity of pazopanib in chemoresistant patients with germ cell tumours (GCT): Early findings of the open-label, single-group, phase 2 pazotest-01 trial by Necchi, A, Mariani, L, Giannatempo, P, Nicolai, N, Farè, E, Piva, L, Biasoni, D, Catanzaro, M, Torelli, T, Stagni, S, Maffezzini, M, Crestani, A, Togliardi, E, Salvioni, R, Gianni, A.M

Get full text